Fruquintinib as Maintenance Therapy for Advanced Colorectal Cancer After Achieving NED: A Clinical Trial

This clinical trial aims to evaluate the effectiveness and safety of fruquintinib as a maintenance therapy for patients with advanced colorectal cancer (CRC) who have achieved no evidence of disease (NED) after completing adjuvant chemotherapy. Despite surgery and adjuvant therapy, the majority of patients with colorectal liver metastases experience recurrence, highlighting the need for improved treatment strategies. Fruquintinib, a highly selective anti-angiogenic inhibitor, has shown promise in reducing tumor recurrence and prolonging time to recurrence in preclinical and clinical studies. This trial will specifically investigate the clinical benefits and safety profile of fruquintinib as a maintenance therapy in this high-risk patient population. The Chinese Society of Clinical Oncology (CSCO) guidelines have already included fruquintinib as a level I recommendation for third-line therapy in CRC, further supporting its potential in this setting. The findings of this study will provide valuable insights into the use of fruquintinib as a maintenance strategy to improve long-term outcomes for patients with advanced CRC.